Ascletis Pharma Inc Ordinary Shares 01672
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 1.39
- Day Range
- HKD 1.32–1.40
- 52-Week Range
- HKD 1.21–2.53
- Bid/Ask
- HKD 1.33 / HKD 1.35
- Market Cap
- HKD 1.37 Bil
- Volume/Avg
- 1.6 Mil / 792,080
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 23.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 6.21%
Company Profile
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 219
- Website
- https://www.ascletis.com
Comparables
Valuation
Metric
|
01672
|
01167
|
02877
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 6.71 |
Price/Book Value | 0.56 | 1.40 | 0.93 |
Price/Sales | 23.84 | 19.79 | 1.43 |
Price/Cash Flow | — | — | 6.32 |
Price/Earnings
01672
01167
02877
Financial Strength
Metric
|
01672
|
01167
|
02877
|
---|---|---|---|
Quick Ratio | 16.51 | 5.67 | 2.97 |
Current Ratio | 16.58 | 5.70 | 3.35 |
Interest Coverage | −1,693.40 | −47.87 | 419.36 |
Quick Ratio
01672
01167
02877
Profitability
Metric
|
01672
|
01167
|
02877
|
---|---|---|---|
Return on Assets (Normalized) | −5.34% | −21.84% | 10.83% |
Return on Equity (Normalized) | −5.59% | −31.75% | 13.16% |
Return on Invested Capital (Normalized) | −9.56% | −26.98% | 12.66% |
Return on Assets
01672
01167
02877
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cfmmlwxcxr | Psqhy | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sjnyjyzwy | Mndwqm | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bxqszkxl | Xhrzpt | $106.7 Bil | |
MRNA
| Moderna Inc | Pkdqmszqj | Blwv | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Fysjcbv | Csll | $22.4 Bil | |
ARGX
| argenx SE ADR | Jdjxbxfs | Ccmv | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rpzqgmmp | Cxsnmr | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ybvsfwl | Wqhnd | $14.6 Bil | |
INCY
| Incyte Corp | Dbvddmhq | Rbrxk | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gxtgybqhq | Fxgvfcd | $12.6 Bil |